Potent adjuvant activity of cationic liposome-DNA complexes for genital herpes vaccines - Wikidata - wikimedia - TriplyDB

Potent adjuvant activity of cationic liposome-DNA complexes for genital herpes vaccines

Potent adjuvant activity of cationic liposome-DNA complexes for genital herpes vaccines

http://www.wikidata.org/entity/Q37190935

about

A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine A cationic liposome-DNA complexes adjuvant (JVRS-100) enhances the immunogenicity and cross-protective efficacy of pre-pandemic influenza A (H5N1) vaccine in ferrets.The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs Effects of herpes simplex virus type 2 glycoprotein vaccines and CLDC adjuvant on genital herpes infection in the guinea pig.Mucosal immunization with liposome-nucleic acid adjuvants generates effective humoral and cellular immunity.Treatment with cationic liposome-DNA complexes (CLDCs) protects mice from lethal Western equine encephalitis virus (WEEV) challenge.Learning from the messengers: innate sensing of viruses and cytokine regulation of immunity - clues for treatments and vaccines.HSV-2 vaccine: current status and insight into factors for developing an efficient vaccine.Cationic liposomes as vaccine adjuvants.Sensing herpes: more than toll.Cationic liposomal vaccine adjuvants in animal challenge models: overview and current clinical status.Liposomal delivery of p-ialB and p-omp25 DNA vaccines improves immunogenicity but fails to provide full protection against B. melitensis challenge.HSV-1-induced chemokine expression via IFI16-dependent and IFI16-independent pathways in human monocyte-derived macrophages.Pyriproxyfen enhances the immunoglobulin G immune response in mice.Immunization with DNA vaccine expressing herpes simplex virus type 1 gD and IL-21 protects against mouse herpes keratitis.A Soybean Oil-Based Liposome-Polymer Transfection Complex as a Codelivery System for DNA and Subunit Vaccines

P2860

Q21089976-CA0992D3-2A58-41CD-92E5-B9352E8A5EB6 Q30385570-2B490E7C-4EE6-48FA-A201-71B5C94D2219 Q33820412-8782CD41-C263-4B55-BDCD-2C91B95667A2 Q34856138-4E6B2E80-E4B4-40F2-92DE-59F5B4BA3CAA Q36517179-C34B6C2F-4576-4EE1-8DBC-37EFCFE386AD Q36599525-C131D022-097A-44A2-8843-9636179657A0 Q36807121-A14D59BA-BFDF-4EE8-A599-78CB5AAFCE05 Q37611796-09F390FD-C6D6-45C1-9D51-AE0B5F482AA2 Q37867105-BDBE2E39-20FA-40F0-AB02-66C09F58E5E4 Q37948677-E0A716F1-DC19-4DA9-87D8-4E57BF87FE6D Q38028994-89BA59F8-C9C2-499E-AE87-13998A9D85DA Q41761576-42122592-E112-4ADE-9DB1-755DAD329CA5 Q42412053-9A65E4C3-8B0D-426B-BCCB-E74AF3E3A60B Q45072385-174B3473-4B17-46A0-BB32-5B0F5AF236E8 Q45370073-9E02B592-1F32-42FC-B419-09D1E239718B Q58909753-323C4069-5C3E-47BC-81A0-D9D5D10F9B14

P2860

Potent adjuvant activity of cationic liposome-DNA complexes for genital herpes vaccines

http://www.wikidata.org/entity/Q37190935

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 11 March 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Potent adjuvant activity of cationic liposome-DNA complexes for genital herpes vaccines

@en

Potent adjuvant activity of cationic liposome-DNA complexes for genital herpes vaccines.

@nl

type

label

Potent adjuvant activity of cationic liposome-DNA complexes for genital herpes vaccines

@en

Potent adjuvant activity of cationic liposome-DNA complexes for genital herpes vaccines.

@nl

prefLabel

Potent adjuvant activity of cationic liposome-DNA complexes for genital herpes vaccines

@en

Potent adjuvant activity of cationic liposome-DNA complexes for genital herpes vaccines.

@nl

P1433

Q37190935-5A9AB8E1-F98A-40DF-9A66-5995A56BA50D

P1476

Q37190935-ED09C4BA-5AA6-460C-8976-6B647489A4C2

P2093

Q37190935-3279DFAE-6769-4DFB-B0A5-E985CD80C55A

Q37190935-3C556C01-BF12-433E-B69D-1CBD29048DBF

Q37190935-560FBA74-B52A-43F7-949B-1C86A43D2A0E

Q37190935-68412EA0-78A0-4EDC-95CC-67DD1AE3C3A7

Q37190935-84C22726-47D6-451A-BAB0-9C0216CB0660

Q37190935-AF3D1F62-35E5-4438-B67D-C663893C1D02

Q37190935-E22377B0-95A4-42C1-A4FF-7956EA434BE6

Q37190935-FA295210-0D19-4BE6-A48B-B634A942B3F3

P2860

Q37190935-01F07740-D2F8-44CB-B909-BE88DF8F976D

Q37190935-07062A4E-7127-4C3E-82FD-4066BBB70062

Q37190935-0972418E-27CC-4444-A1C4-6DE804E34A83

Q37190935-1B551683-5A59-4DEA-8D9B-1AB780E03236

Q37190935-1C635EC4-4F4E-40B7-A6A6-4E311FEB1B80

Q37190935-29F8A086-3455-4115-9C8F-F71227807688

Q37190935-2AD7D6BF-D964-475D-AE49-6E45604B4B31

Q37190935-2FCEDB30-3B23-43BB-B1C0-1FFC3D18CC8E

Q37190935-3B98C82B-935C-4353-BED4-A86D385050FF

Q37190935-3CA3EBCC-F6A7-4936-97EC-B92411B7121C

P304

Q37190935-962D88F3-0CB8-441D-82EA-B2A7D5B947D5

P31

Q37190935-B77405E5-90E7-4158-8FF3-C16483B6F893

P356

Q37190935-43A06AF6-525F-474B-844A-3D48F6053221

P433

Q37190935-1EDE291D-AF1C-4891-82D6-22CABE5D3186

P478

Q37190935-BBE67ED3-4148-48EA-B833-D8F975CC9146

P577

Q37190935-AC2891B9-088C-42D5-8686-F4F60D9FB8AE

P698

Q37190935-3BA449BF-904A-44D2-896A-996817D8D5D6

P932

Q37190935-12F91B5C-372C-4CB3-A0D1-6639F6C25E58

P356

P1433

Clinical and Vaccine Immunology

P1476

Potent adjuvant activity of cationic liposome-DNA complexes for genital herpes vaccines

@en

P2093

Claudia Chalk

http://www.w3.org/2001/XMLSchema#string

David I Bernstein

http://www.w3.org/2001/XMLSchema#string

Fernando J Bravo

http://www.w3.org/2001/XMLSchema#string

Jane E Strasser

http://www.w3.org/2001/XMLSchema#string

Jeff Fairman

http://www.w3.org/2001/XMLSchema#string

Marla Lay

http://www.w3.org/2001/XMLSchema#string

Nicholas Farley

http://www.w3.org/2001/XMLSchema#string

Rhonda D Cardin

http://www.w3.org/2001/XMLSchema#string

P2860

Reducing the risk of transmitting genital herpes: advances in understanding and therapy

Herpes simplex virus infections of the newborn

IRF-7 is the master regulator of type-I interferon-dependent immune responses

Examination of the kinetics of herpes simplex virus glycoprotein D binding to the herpesvirus entry mediator, using surface plasmon resonance

Recent progress in herpes simplex virus immunobiology and vaccine research

Dendrimers, a new class of candidate topical microbicides with activity against herpes simplex virus infection

Genital herpesvirus hominis infection in mice. I. Development of an experimental model.

Effect of ribavirin on Type 2 Herpesvirus hominis (HVH/2) in vitro and in vivo.

Vaccine adjuvants: current state and future trends.

P304

699-705

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/CVI.00370-08

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2009-03-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19279167

http://www.w3.org/2001/XMLSchema#string

P932

2681593

http://www.w3.org/2001/XMLSchema#string